Psychedelics: Science sabotaged by Social Media
Neuropharmacology January 21, 2023 Edward M. Sellers, Myroslava K. Romach 21 citations
Developing microdoses of psychedelics could overcome many scientific and regulatory hurdles that hinder high-dose psychedelic drug development. If microdosing proves efficacious and safe for long-term use, it could be administered through the typical outpatient model for mental disorders, which would be more cost-effective than the high-dose/intense psychotherapy model. Outpatient psychotherapeutic agents have a clear approval route and would likely avoid the extensive Risk Evaluation and Mitigation Strategy required for high-dose use. The article suggests there may be different therapeutic roles for both high and low dose psychedelic agents.